MARKET

NERV

NERV

Minerva
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.36
-0.71
-7.78%
After Hours: 8.36 0 0.00% 16:41 01/17 EST
OPEN
9.07
PREV CLOSE
9.07
HIGH
9.23
LOW
8.24
VOLUME
361.55K
TURNOVER
--
52 WEEK HIGH
9.23
52 WEEK LOW
4.010
MARKET CAP
326.25M
P/E (TTM)
-5.8745
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of NERV and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

NERV News

  • The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares
  • Benzinga.1d ago
  • Minerva Neurosciences Announces Completion of Patient Screening in Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
  • GlobeNewswire.01/06 13:00
  • Investors flock to neuro drug makers after FDA approves new schizophrenia drug
  • MarketWatch.12/23/2019 19:47
  • Minerva shares fall on failed depression drug trial
  • MarketWatch.12/19/2019 20:07

More

Industry

Biotechnology & Medical Research
-0.16%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About NERV

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson's disease. MIN-101 is a compound that blocks serotonin receptors and sigma receptors, two receptors in the brain that are involved in the regulation of mood, cognition, sleep and anxiety. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-hydroxytryptamine type 1A (5-HT1A). MIN-202 is a selective orexin 2 receptor antagonist. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1) protein, for the treatment of Parkinson's disease.
More

Webull offers Minerva Neurosciences Inc (NERV) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.